Drugs / DetoxPC
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy2 trials | ||||||
| Phase 1 | NCT00003974 Background | Aug 1997 → Jun 1998 | lung cancer, malignant mesothelioma | Roswell Park Cancer Institute | Completed | No outcome recorded |
| Phase 2 | NCT00019331 Background | Oct 1997 → May 2007 | colorectal cancer, cutaneous melanoma, endometrial cancer, head and neck cancer +4 | National Cancer Institute (NCI) | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DetoxPC | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00003974 ↗ |
| Route | Subcutaneous | “Patients receive tumor-specific ras peptide vaccine with DetoxPC subcutaneously (SC) once every 5 weeks for 3 courses.” NCT00019331 ↗ |